ESC 365 - Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial

ESC Premium Access

Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial

Session: Can we improve outcomes by targeting metabolic risk?

Topic: Pharmacotherapy

Speaker: Doctor M. Segar (Houston, US)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Doctor Matthew Segar

Texas Heart Institute, Houston (United States of America)

0 follower

4 more presentations in this session

Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies.

Speaker: Professor M. Banach (Lodz, PL)

Impact of early initiation of SGLT2 inhibitor on cardiovascular outcomes in diabetic patients with known atherosclerotic cardiovascular disease or risk factors: propensity score matched analysis

Speaker: Doctor W. Sun (Shatin, HK)

Changes in EPA and DHA during supplementation with Omega-3 fatty acids and incident cardiovascular events: secondary analysis from the OMEMI trial

Speaker: Doctor P. Myhre (Nordbyhagen, NO)

Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial

Speaker: Doctor F. Cosentino (Stockholm, SE)

Access the full session

Can we improve outcomes by targeting metabolic risk?

Speakers: Doctor M. Segar, Professor M. Banach, Doctor W. Sun, Doctor P. Myhre, Doctor F. Cosentino

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by